Literature DB >> 27018798

Targeted therapeutics for severe refractory asthma: monoclonal antibodies.

Christopher L Grainge1,2, Steven Maltby1, Peter G Gibson1,2, Peter A B Wark1,2, Vanessa M McDonald1,2.   

Abstract

Severe asthma is a complex multifactorial disease that requires specialist multidisciplinary input for optimal clinical outcomes. Following multidimensional assessment for optimisation of current therapy, self-management skills and comorbidities, all patients should be accurately phenotyped. Only after this assessment has been completed should new monoclonal antibody therapies be considered. In this review, we summarise the new antibody approaches targeting identified pathological pathways in severe refractory asthma.

Entities:  

Keywords:  Severe asthma; biomarker; monoclonal; multidimensional assessment; phenotype; targeted therapy; treatment-refractory asthma

Mesh：

Substances：

Year:  2016        PMID： 27018798     DOI： 10.1586/17512433.2016.1172208

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN： 1751-2433            Impact factor:   5.045


  9 in total

1.  Nanoformulated ABT-199 to effectively target Bcl-2 at mitochondrial membrane alleviates airway inflammation by inducing apoptosis.

Authors:  Bao-Ping Tian; Fangyuan Li; Ruiqing Li; Xi Hu; Tian-Wen Lai; Jingxiong Lu; Yun Zhao; Yang Du; Zeyu Liang; Chen Zhu; Wei Shao; Wen Li; Zhi-Hua Chen; Xiaolian Sun; Xiaoyuan Chen; Songmin Ying; Daishun Ling; Huahao Shen
Journal:  Biomaterials       Date:  2018-06-18       Impact factor: 12.479

Review 2.  Monoclonal Antibodies for Treatment of Eosinophilic Esophagitis.

Authors:  Mahsa Eskian; MirHojjat Khorasanizadeh; Amal H Assa'ad; Nima Rezaei
Journal:  Clin Rev Allergy Immunol       Date:  2018-08       Impact factor: 8.667

Review 3.  Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand.

Authors:  John Blakey; Li Ping Chung; Vanessa M McDonald; Laurence Ruane; John Gornall; Chris Barton; Sinthia Bosnic-Anticevich; John Harrington; Mark Hew; Anne E Holland; Trudy Hopkins; Lata Jayaram; Helen Reddel; John W Upham; Peter G Gibson; Philip Bardin
Journal:  Respirology       Date:  2021-09-29       Impact factor: 6.175

Review 4.  Living well with severe asthma.

Authors:  Michelle A Stubbs; Vanessa L Clark; Vanessa M McDonald
Journal:  Breathe (Sheff)       Date:  2019-06

5.  Imaging for precision medicine: can V-P SPECT measure mepolizumab response in asthma?

Authors:  Vanessa M McDonald; Paola D Urroz; Marika Bajc; Natalie Rutherford; Bree Brooker; Peter G Gibson
Journal:  Respirol Case Rep       Date:  2021-02-01

6.  "It's like being on a roller coaster": the burden of caring for people with severe asthma.

Authors:  Eleanor C Majellano; Vanessa L Clark; Juliet M Foster; Peter G Gibson; Vanessa M McDonald
Journal:  ERJ Open Res       Date:  2021-04-12

7.  Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap.

Authors:  Luisa Ricciardi; Francesco Papia; Marta Liotta; Francesca Cicero; Stefania Isola; Gennaro Tartarisco; Fabiana Furci; Sebastiano Gangemi
Journal:  Postepy Dermatol Alergol       Date:  2022-02-28       Impact factor: 1.837

8.  Severe Asthma Toolkit: an online resource for multidisciplinary health professionals-needs assessment, development process and user analytics with survey feedback.

Authors:  Steven Maltby; Peter G Gibson; Helen K Reddel; Lorraine Smith; Peter A B Wark; Gregory G King; John W Upham; Vanessa L Clark; Mark Hew; Louisa Owens; Stephen Oo; Alan L James; Bruce Thompson; Guy B Marks; Vanessa M McDonald
Journal:  BMJ Open       Date:  2020-03-24       Impact factor: 2.692

9.  Six gene and TH2 signature expression in endobronchial biopsies of participants with asthma.

Authors:  Stephany Sánchez-Ovando; Katherine J Baines; Daniel Barker; Peter A Wark; Jodie L Simpson
Journal:  Immun Inflamm Dis       Date:  2020-01-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.